MarketLens
Sign Up

What Does Vir Biotechnology's Astellas Deal Mean for Its Future

8 months ago
SHARE THIS ON:

What Does Vir Biotechnology's Astellas Deal Mean for Its Future

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

Vir Biotechnology appointed Aziz Sawaf as Chief Financial Officer, effective immediately, per a company announcement. The leadership change puts a new executive in charge of the biotech's financial st...
Stock News•1 months ago

Vir Biotechnology: Astellas Deal Highlights The Platform's Value

Vir Biotechnology secured $335M in upfront and near-term payments plus a premium equity investment from Astellas, validating its PRO-XTEN platform. The deal adds a second revenue engine alongside a fu...
Stock News•1 months ago

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A activity surged in 2026, putting ABVX, IOVA, VKTX, and BCRX on takeover watchlists as drugmakers seek late-stage and commercial assets.

Breaking News

View All →

Top Headlines

View More →
Stock News•43 minutes ago

Apple posts record September quarter under new CEO as iPhone, Mac sales surge

Stock News•55 minutes ago

Alphabet Lost $500 Billion in Market Value. Should You Really Buy AI Stocks Now?

Stock News•59 minutes ago

Apple Q4: Another Solid Result

Stock News•59 minutes ago

Molly Pieroni Names GOOGL & MSFT Strong Investments in "Topsy-Turvy" Market

Stock News•1 hour ago

Apple Looks Very Smart in Modest AI Spend: Tom Forte